Published on 01 January 2025

<b>Cambritaxestat</b><b> Reduces Tumor Growth</b> in mGC models

View Dataset
Centonze, Matteo

Description

The study confirmed the efficacy of therapy targeting the ATX/LPA axis in advanced GC. Cambritaxestat, an ATX inhibitor with oral bioavailability and tolerability, is a promising candidate for combination with standard chemotherapy or antiangiogenic therapies, helping to overcome resistance and adapt conventional strategies.

Citations (0)

Mentions (0)

Metrics Over Time

Publication Details

Keywords

Cancer therapy (excl. chemotherapy and radiation therapy)Cancer cell biologyMolecular targetsPredictive and prognostic markers